Implications of Measuring Soluble Receptor Activators of Nuclear Factor-κB Ligand and Osteoprotegerin in Bone Metabolism of Elderly Women

被引:18
作者
Chiba, Yuko [2 ]
Onouchi, Tsuneko [3 ]
Ikeda, Toru [4 ]
Adachi, Junichiro [2 ]
Tamura, Yoshiaki [2 ]
Horiuchi, Toshiyuki [1 ,2 ]
机构
[1] Tokyo Metropolitan Toshima Hosp, Dept Endocrinol & Metab, Itabashi Ku, Tokyo, Japan
[2] Tokyo Metropolitan Geriatr Hosp, Dept Endocrinol, Tokyo, Japan
[3] Teikyo Univ, Sch Med, Lab Collaborat Res, Tokyo 173, Japan
[4] Nagasaki Univ, Grad Sch Biochem Sci, Dept Oral Pathol & Bone Metab, Nagasaki 852, Japan
关键词
Soluble RANKL; Osteoprotegerin; Osteoporosis; Elderly women; OSTEOCLAST DIFFERENTIATION; INHIBITORY FACTOR; SERUM-LEVELS; SYSTEM; MASS; AGE;
D O I
10.1159/000196280
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Background/Aim: The discovery of a signaling system consisting of a soluble receptor activator of the NF-kappa B ligand (sRANKL) and its decoy receptor osteoprotegerin (OPG) has provided a valuable key to understanding the pathophysiology of the bone microenvironment. We conducted a cross-sectional study of the role of sRANKL and OPG levels as they relate to bone metabolism in elderly postmenopausal women with and without osteoporosis. Subjects and Methods: Fifty-one elderly women with or without osteoporosis were enrolled in the study. Bone alkaline phosphatase, osteocalcin, urinary deoxypyridinoline and urinary type I collagen N-terminal telopeptide (NTx) were measured as bone metabolic markers. Serum levels of OPG and sRANKL were measured by sandwich enzyme-linked immunosorbent assay and the lumbar spine bone mineral density (LSBMD) with dual-energy X-ray absorptiometry. Furthermore, we compared the sRANKL and OPG levels in elderly women with and without vertebral fractures (VFs). Results: In elderly postmenopausal women, there was a significant positive association between OPG levels and the T score and Z score of LSBMD (r = 0.345 and p = 0.014 for T score; r = 0.438 and p = 0.001 for Z score). sRANKL levels were not significantly correlated with T score, Z score of LSBMD, or any of the four bone metabolic markers. There were no significant differences in the sRANKL levels among the three groups (normal bone mineral density, osteopenia, and osteoporosis), but a trend toward a higher value in the osteoporosis group. The sRANKL/OPG ratio was negatively correlated with the T score and Z score of LSBMD (r = -0.336, p = 0.017; r = -0.384, p = 0.006, respectively), but not with any of the four bone metabolic markers. OPG levels in elderly women with VFs were lower than in those without VFs (p = 0.05). Multiple regression analysis showed that OPG and NTx are contributing factors to bone loss in elderly women (p = 0.014 and 0.012, respectively). Conclusion: The OPG level provides a good predictor of osteoporosis as well as NTx in elderly women; additionally, the findings suggest that OPG might protect elderly women from bone loss or fractures. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:275 / 280
页数:6
相关论文
共 22 条
[1]   The effect of a single dose of osteoprotegerin in postmenopausal women [J].
Bekker, PJ ;
Holloway, D ;
Nakanishi, A ;
Arrighi, M ;
Leese, PT ;
Dunstan, CR .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (02) :348-360
[2]  
Chen D, 2001, CLIN CHEM, V47, P747
[3]  
Dovio A, 2005, J Endocrinol Invest, V28, P14
[4]   Role of RANK ligand in mediating increased bone resorption in early postmenopausal women [J].
Eghbali-Fatourechi, G ;
Khosla, S ;
Sanyal, A ;
Boyle, WJ ;
Lacey, DL ;
Riggs, BL .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (08) :1221-1230
[5]  
Fahrleitner-Pammer A, 2003, WIEN KLIN WOCHENSCHR, V115, P291, DOI 10.1007/BF03040334
[6]   Plasma levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in patients with neuroblastoma [J].
Granchi, D ;
Garaventa, A ;
Amato, I ;
Paolucci, P ;
Baldini, N .
INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (01) :146-151
[7]  
Hawa Gerhard, 2003, Clin Lab, V49, P461
[8]   Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases [J].
Hofbauer, LC ;
Schoppet, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (04) :490-495
[9]   Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells [J].
Hofbauer, LC ;
Khosla, S ;
Dunstan, CR ;
Lacey, DL ;
Spelsberg, TC ;
Riggs, BL .
ENDOCRINOLOGY, 1999, 140 (09) :4367-4370
[10]   Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios [J].
Jorgensen, HL ;
Kusk, P ;
Madsen, B ;
Fenger, M ;
Lauritzen, JB .
JOURNAL OF BONE AND MINERAL METABOLISM, 2004, 22 (02) :132-138